Movement Alert｜GRAIL, Inc. Falls 5.01% in Regular Trading, FDA Review Tailwind and Target Price Hike Remain in Focus

Market Focus10-22

On October 22, GRAIL, Inc. fell 5.01% in Regular Trading, trading at $125.86 per share, with turnover of $24.8928 million.

The key catalyst in focus remained the company’s Galleri multi-cancer early detection test, which was previously recommended by an FDA advisory committee, followed by UBS raising its target price to $175 from $105 while maintaining a buy rating.

According to the disclosed review outcome, the advisory committee voted 10 to 0 on safety, 6 to 4 on effectiveness, and 7 to 2 with 1 abstention on benefit-risk. Recent market discussion has increasingly shifted toward product positioning and labeling rather than core safety concerns, reinforcing expectations for regulatory progress and eventual commercialization, even as the stock pulled back during the session.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment